Overview

This is a prospective observational cohort study (AI-Kidney-Prognosis), aiming to non-invasively predict the clinical outcomes in renal cell carcinoma patients after surgical treatment using radiomics-based AI models, thereby assisting clinical decision-making and personalized follow-up strategies.

Eligibility

Inclusion Criteria:

1. Patients were treated for renal cell carcinoma in Wuhan Union Hospital from August 2025 to August 2026;
2. Aged > 18 years old;
3. At least one abdominal CT scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of renal cell carcinoma.

Exclusion Criteria:

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than renal cell carcinoma;
4. Unclear pathological diagnosis.